Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Der nächste Perpetua? Warum NevGolds neueste Bohrergebnisse den Vergleich mit dem Milliardenwert PPTA nähren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
22.05.ASCO: Cullinan, Taiho unveil lung cancer data behind FDA application plans
22.05.Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs
22.05.Eikon blames US funding cuts for 15% staff reduction centered on research tools business
22.05.Sanofi inks $470M Vigil Neuroscience buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
21.05.France invests €1.3M into novel mRNA project led by OSE Immunotherapeutics
21.05.Merck KGaA shares data justifying pushing lupus drug into phase 3-despite recent setback
21.05.Moderna withdraws FDA filing for flu/COVID combination vaccine, plans resubmission with efficacy data
21.05.Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B
21.05.Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win
20.05.PureTech shows durability of pulmonary fibrosis candidate deupirfenidone
20.05.Schrödinger lays off 60 staffers amid 'uncertain times and challenging economic conditions'
20.05.BioNTech pledges £1B to bolster UK presence while nabbing £129M grant from government
20.05.Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential
20.05.SV Health's latest pharma-backed dementia fund raises $269M to invest in new therapies
20.05.RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies
20.05.Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck
20.05.Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease
19.05.Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off staff
19.05.Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2
19.05.Pfizer-backed CellCentric secures $120M for further myeloma trials
19.05.'Not game-changing': Boehringer's phase 3 lung data get muted response from analysts
19.05.Armata links bacteria-killing virus to clinical responses in phase 2 trial
19.05.Applied's rare disease drug suffers another phase 3 failure months after FDA rejection
16.05.ASGCT: Neurogene details new safety measures after young patient's death in AAV gene therapy trial
16.05.ASGCT: Analysts see Rocket gene therapy setting 'a new bar' for efficacy in heart condition